Effect of Folic Acid Supplementation on Indices of Glycemic Control, Insulin Resistance and Lipid Profile in Patients With Type 2 Diabetes Mellitus

Aghamohammadi khiavi, V.; Pourghassem Gargari, B.; Aliasgharzadeh, A.
November 2011
Iranian Journal of Endocrinology & Metabolism;Nov2011, Vol. 13 Issue 4, p424
Academic Journal
Introduction: This study was performed to determine the effects of supplementation of folate on indices of glycemic control, insulin resistance and lipid profile in in men with type 2 diabetes, under metformin (at least 1500mg daily) treatment. Materials and Methods: This was a double-blind randomized controlled clinical trial, in which 68 men with type 2 diabetes participated with written consents. Patients were randomly divided in two groups; folic acid 5mg/day and placebo. All the patients received the tablets for 8 weeks. Anthropometric and nutrient intakes data were obtained from each patient, and baseline and 8th week fasting blood glucose, HbA1C, serum insulin, insulin resistance, serum total cholestrol, TG, LDL-C, HDL-C, serum folate and plasma homocysteine were measured. Results: Supplementation with folic acid led to 6.3 percent decrease in HbA1C (P=0.019), 9.5 percent decrease in fasting blood glucose (P=0.006), 15.1 percent decrease in serum insulin (P=0.028), 17.2 percent decrease in insulin resistance (P=0.043) and 20 percent decrease in plasma homocysteine (P<0.001), 18.4 percent increase in serum folate (P<0.001). No significant changes occurred in the placebo group (P>0.05). Conclusion: A pharmacological dose of folic acid supplementation decreased plasma level of homocysteine and improved glycemic control, insulin resistance and folate levels, a finding which sugqests a safe and inexpensive therapy for lowering homocysteine and improving the overall management of diabetic patients.


Related Articles

  • Effects of a Flaxseed-Derived Lignan Supplement in Type 2 Diabetic Patients: A Randomized, Double-Blind, Cross-Over Trial. An Pan; Jianqin Sun; Yanqiu Chen; Xingwang Ye; Huaixing Li; Zhijie Yu; Yanfang Wang; Wenjia Gu; Xinyi Zhang; Xiafei Chen; Demark-Wahnefried, Wendy; Yong Liu; Xu Lin // PLoS Clinical Trials;Nov2007, Vol. 4 Issue 11, p1 

    Background. Flaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles and insulin...

  • Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. Tanaka, Kumiko; Saisho, Yoshifumi; Manesso, Erica; Tanaka, Masami; Meguro, Shu; Irie, Junichiro; Sugiura, Hiroaki; Kawai, Toshihide; Jinzaki, Masahiro; Cobelli, Claudio; Itoh, Hiroshi // Clinical Drug Investigation;Oct2015, Vol. 35 Issue 10, p675 

    Background and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are becoming one of the major therapeutic options for the treatment of type 2 diabetes mellitus (T2DM). This study was conducted as an exploratory analysis to clarify the effects of liraglutide, a GLP-1RA, on beta...

  • Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis. Gu, Shuyan; Shi, Jihao; Tang, Zhiliu; Sawhney, Monika; Hu, Huimei; Shi, Lizheng; Fonseca, Vivian; Dong, Hengjin // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: Metformin is the first-line oral hypoglycemic agent for type 2 diabetes mellitus recommended by international guidelines. However, little information exists comparing it with acarbose which is also commonly used in China. This study expanded knowledge by combining direct and...

  • Light therapy for better mood and insulin sensitivity in patients with major depression and type 2 diabetes: a randomised, double-blind, parallel-arm trial. Brouwer, Annelies; van Raalte, Daniël H.; Diamant, Michaela; Rutters, Femke; van Someren, Eus J. W.; Snoek, Frank J.; Beekman, Aartjan T. F.; Bremmer, Marijke A. // BMC Psychiatry;2015, Vol. 15 Issue 1, p1 

    Background: Major depression and type 2 diabetes often co-occur. Novel treatment strategies for depression in type 2 diabetes patients are warranted, as depression in type 2 diabetes patients is associated with poor prognosis and treatment results. Major depression and concurrent sleep disorders...

  • Fighting Obesity and High Blood Sugar. GOEPP, JULIUS // Life Extension;Nov2010, Vol. 16 Issue 11, p46 

    The article reports on the health benefits that have been associated with the anti-diabetes drug metformin, including the reduction of blood sugar and weight gain, the prevention of several types of cancer and a slowing of the human aging process. A discussion of research which has investigated...

  • thiazolidinediones. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p740 

    An encyclopedia entry for "thiazolidinediones" is presented. It pertains to a group of oral hypoglycaemics that are utilized in the treatment of type 2 diabetes mellitus. Thiazolidinedione is sometimes pertained as glitazones. It functions by cutting the body cells' resistance to insulin and are...

  • Metabolic disease: Mitochondrial uncoupler reverses diabetes. Crunkhorn, Sarah // Nature Reviews Drug Discovery;Dec2014, Vol. 13 Issue 12, p885 

    The article discusses the development of insulin resistance and hyperglycaemia which use to treat type 2 diabetes (T2D) by reducing the accumulation of lipids in metabolically sensitive organs. It examines the impact of mitochondrial uncoupler to energy inefficiency and increased energy...

  • Maximize benefits of metform in DM2. Kuritzky, Louis // Primary Care Reports;May2010 Supplement, p9 

    The article discusses research being done on the efficacy of metformin monotherapy in controlling glucose in type 2 diabetes, which references a study by J. B. Brown and colleagues published in a 2010 issue of the journal "Diabetes Care."

  • For type 2 diabetes, after metformin, what next? Kuritzky, Louis // Primary Care Reports;Jul2010 Clinical Briefs, p14 

    The article discusses the therapeutic choices for type-2 diabetes following initial treatment with metformin.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics